Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-268122
Filing Date
2025-11-06
Accepted
2025-11-06 08:00:45
Documents
67
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mura-20250930.htm   iXBRL 10-Q 2529067
2 EX-31.1 mura-ex31_1.htm EX-31.1 18816
3 EX-31.2 mura-ex31_2.htm EX-31.2 18867
4 EX-32.1 mura-ex32_1.htm EX-32.1 11177
5 EX-32.2 mura-ex32_2.htm EX-32.2 11229
  Complete submission text file 0001193125-25-268122.txt   8239429

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mura-20250930.xsd EX-101.SCH 917314
69 EXTRACTED XBRL INSTANCE DOCUMENT mura-20250930_htm.xml XML 1356996
Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41837 | Film No.: 251456248
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)